At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DCTH DELCATH SYSTEMS INC
Market Closed 12-20 16:00:00 EST
11.01
-0.17
-1.52%
盘后11.01
+0.000.00%
19:38 EST
High11.28
Low10.84
Vol458.91K
Open11.15
D1 Closing11.18
Amplitude3.98%
Mkt Cap352.03M
Tradable Cap279.76M
Total Shares31.97M
T/O5.07M
T/O Rate1.81%
Tradable Shares25.41M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Delcath Systems (DCTH) Gets a Buy from Craig-Hallum
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.